美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CNXU近 30 天 2 則 · 第 1 / 1 頁
- A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
- Conexeu Sciences Sets September and October 2026 Conference Schedule
- Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
- Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
- Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
- The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
- A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
- Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
- Is Conexeu Sciences (CNXU) Quietly Redefining Its Commercial Ambitions With CXU Platform Moves?
- Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
- Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
- Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026
- How Investors Are Reacting To Conexeu Sciences (CNXU) 3D-Printed Bioregenerative Breast Matrix Initiative
- UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。